{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T17:10:09Z","timestamp":1760202609425},"reference-count":90,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1645,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1177\/0091270010372107","type":"journal-article","created":{"date-parts":[[2010,5,26]],"date-time":"2010-05-26T02:31:38Z","timestamp":1274841098000},"page":"292-300","source":"Crossref","is-referenced-by-count":15,"title":["Safety of Plasma Volume Expanders"],"prefix":"10.1002","volume":"51","author":[{"given":"Albert","family":"Farrugia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,7]]},"reference":[{"key":"10.1177\/0091270010372107-BIB1|cit1","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/cc968","article-title":"Pathophysiology of fluid imbalance","volume":"4","author":"Kreimeier","year":"2000","journal-title":"Crit Care"},{"key":"10.1177\/0091270010372107-BIB2|cit2","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0140-6736(02)92543-2","article-title":"Observations of transfusion of blood","volume":"2","author":"Blundell","year":"1829","journal-title":"Lancet"},{"key":"10.1177\/0091270010372107-BIB3|cit3","volume-title":"Department of Health and Human Services, Food and Drug Administration Center for Biologics Evaluation and Research","author":"Finlayson","year":"September 17,1998"},{"key":"10.1177\/0091270010372107-BIB4|cit4","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1001\/jama.1915.02570350015004","article-title":"The intravenous use of colloidal (gelatin) solutions in shock","volume":"64","author":"Hogan","year":"1915","journal-title":"JAMA"},{"key":"10.1177\/0091270010372107-BIB5|cit5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0950-3501(97)80003-7","article-title":"The crystalloid versus colloid controversy: present status","volume":"11","author":"Hillman","year":"1997","journal-title":"Bailliere's Clin Anaestesiol"},{"key":"10.1177\/0091270010372107-BIB6|cit6","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1186\/cc2851","article-title":"Clinical review: hemorrhagic shock","volume":"8","author":"Gutierrez","year":"2004","journal-title":"Crit Care"},{"key":"10.1177\/0091270010372107-BIB7|cit7","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1001\/archinte.1991.00400050051011","article-title":"The use of albumin in clinical practice","volume":"151","author":"Erstad","year":"1991","journal-title":"Arch Intern Med"},{"key":"10.1177\/0091270010372107-BIB8|cit8","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1136\/bmj.317.7153.235","article-title":"Human albumin administration in critically ill patients: systematic review of randomized controlled trials","volume":"317","author":"Cochrane Injuries Group Albumin Reviewers","year":"1998","journal-title":"BMJ"},{"key":"10.1177\/0091270010372107-BIB9|cit9","doi-asserted-by":"crossref","first-page":"149","DOI":"10.7326\/0003-4819-135-3-200108070-00007","article-title":"Patient survival after human albumin administration: a meta-analysis of randomized, controlled trials","volume":"135","author":"Wilkes","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1177\/0091270010372107-BIB10|cit10","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1097\/00003246-200105000-00021","article-title":"Safety of human albumin based on spontaneously reported serious adverse events","volume":"29","author":"Hoegen","year":"2001","journal-title":"Crit Care Med"},{"key":"10.1177\/0091270010372107-BIB11|cit11","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/bja\/aeg233","article-title":"Safety of human albumin-serious adverse events reported worldwide in 1998-2000","volume":"91","author":"Vincent","year":"2003","journal-title":"Br J Anaesth"},{"key":"10.1177\/0091270010372107-BIB12|cit12","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa040232","article-title":"SAFE study investigators. A comparison of albumin and saline for fluid resuscitation in the intensive care unit","volume":"350","author":"Finfer","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1177\/0091270010372107-BIB13|cit13","doi-asserted-by":"crossref","first-page":"9417","DOI":"10.1073\/pnas.91.20.9417","article-title":"Analbuminemia: three case resulting from different point mutations in the albumin gene","volume":"91","author":"Watkins","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1177\/0091270010372107-BIB14|cit14","first-page":"664","article-title":"Congenital analbuminaemia: biochemical and clinical implications: a case report and literature review","volume":"163","author":"Koot","year":"2004","journal-title":"Eur J Pediatr"},{"key":"10.1177\/0091270010372107-BIB15|cit15","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1113\/jphysiol.1896.sp000596","article-title":"On the absorption of fluids from the connective tissue spaces","volume":"19","author":"Starling","year":"1896","journal-title":"J Physiol"},{"key":"10.1177\/0091270010372107-BIB16|cit16","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/hep.20720","article-title":"Albumin: biochemical properties and therapeutic potential","volume":"41","author":"Quinlan","year":"2005","journal-title":"Hepatology"},{"key":"10.1177\/0091270010372107-BIB17|cit17","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.4049\/jimmunol.170.9.4793","article-title":"Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis","volume":"170","author":"Wunder","year":"2003","journal-title":"J Immunol"},{"key":"10.1177\/0091270010372107-BIB18|cit18","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/0148607180004004357","article-title":"Incidence and mortality of hypoalbuminemic patients in hospitalized veterans","volume":"4","author":"Reinhardt","year":"1980","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"10.1177\/0091270010372107-BIB19|cit19","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1046\/j.1365-2044.1998.00438.x","article-title":"Serum albumin: touchstone or totem","volume":"53","author":"Margarson","year":"1998","journal-title":"Anaesthesia"},{"key":"10.1177\/0091270010372107-BIB20|cit20","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.tmrv.2009.09.005","article-title":"Albumin usage in clinical medicine: tradition or therapeutic","volume":"24","author":"Farrugia","year":"2010","journal-title":"Transfus Med Rev"},{"key":"10.1177\/0091270010372107-BIB21|cit21","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1021\/ja01207a034","article-title":"Preparation and properties of serum and plasma proteins. IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids","volume":"68","author":"Cohn","year":"1946","journal-title":"J Am Chem Soc"},{"key":"10.1177\/0091270010372107-BIB22|cit22","unstructured":"CSL Bioplasma Product information sheet for albumin http:www.csl.com.audocs746429PT34500100G.pdf May 14, 2010"},{"key":"10.1177\/0091270010372107-BIB23|cit23","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrd2307","article-title":"The FDA's assessment of follow-on protein products: a historical perspective","volume":"6","author":"Woodcock","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1177\/0091270010372107-BIB24|cit24","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1097\/01.CCM.0000142574.00425.E9","article-title":"Morbidity in hospitalized patients receiving human albumin: a meta-analysis of randomized, controlled trials","volume":"32","author":"Vincent","year":"2004","journal-title":"Crit Care Med"},{"key":"10.1177\/0091270010372107-BIB25|cit25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.0042-9007.2004.00386.x","article-title":"The mantra of blood safety: time for a new tune","volume":"86","author":"Farrugia","year":"2004","journal-title":"Vox Sang"},{"key":"10.1177\/0091270010372107-BIB26|cit26","first-page":"858","article-title":"Partitioning and inactivation of viruses by cold ethanol fractionation and pasteurization during manufacture of albumin from human plasma","volume":"10","author":"Kim","year":"2000","journal-title":"J Microbiol Biotechnol"},{"key":"10.1177\/0091270010372107-BIB27|cit27","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1046\/j.1537-2995.1976.16276155108.x","article-title":"Hepatitis B virus and hepatitis B surface antigen in human albumin products","volume":"16","author":"Hoofnagle","year":"1976","journal-title":"Transfusion"},{"key":"10.1177\/0091270010372107-BIB28|cit28","first-page":"429","article-title":"Prevention of virus B hepatitis (SH hepatitis)","volume":"123","author":"Soulier","year":"1972","journal-title":"Am J Dis Child"},{"key":"10.1177\/0091270010372107-BIB29|cit29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1046\/j.1365-3148.1999.009001003.x","article-title":"Assessment of the potential of plasma fractionation processes to remove causative agents of transmissible spongiform encephalopathy","volume":"9","author":"Foster","year":"1999","journal-title":"Transfus Med"},{"key":"10.1177\/0091270010372107-BIB30|cit30","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1046\/j.1537-2995.2001.41081020.x","article-title":"Causality assessment of suspected virus transmission by human plasma products","volume":"41","author":"Schosser","year":"2001","journal-title":"Transfusion"},{"key":"10.1177\/0091270010372107-BIB31|cit31","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/ana.410380223","article-title":"Creutzfeldt-Jakob disease after liver transplantation","volume":"38","author":"Cr\u00e9ange","year":"1995","journal-title":"Ann Neurol"},{"key":"10.1177\/0091270010372107-BIB32|cit32","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0268-960X(98)90007-8","article-title":"New-variant Creutzfeldt-Jakob disease: the risk of transmission by blood transfusion","volume":"12","author":"Turner","year":"1998","journal-title":"Blood Rev"},{"key":"10.1177\/0091270010372107-BIB33|cit33","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/oxfordjournals.aje.a112239","article-title":"An outbreak of type B hepatitis associated with transfusion of plasma protein fraction","volume":"103","author":"Pattison","year":"1976","journal-title":"Am J Epidemiol"},{"key":"10.1177\/0091270010372107-BIB34|cit34","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1056\/NEJM197807132990203","article-title":"Hypotension associated with prekallikrein activator (Hageman-factor fragments) in plasma protein fraction","volume":"299","author":"Alving","year":"1978","journal-title":"N Engl J Med"},{"key":"10.1177\/0091270010372107-BIB35|cit35","first-page":"540","article-title":"Hypotensive effects of plasma protein fraction. The relation between prekallikrein activator, bradykinin generation, and blood pressure in an animal model","volume":"100","author":"Bleeker","year":"1982","journal-title":"J Lab Clin Med"},{"key":"10.1177\/0091270010372107-BIB36|cit36","first-page":"334","article-title":"Impact of manufacturing improvements on clinical safety of albumin: Australian pharmacovigilance data for 1988-2005","volume":"8","author":"Che","year":"2006","journal-title":"Crit Care Resusc"},{"key":"10.1177\/0091270010372107-BIB37|cit37","first-page":"143","article-title":"Development of a process for the preparation of human serum albumin using chromatographic methods","volume":"227","author":"Yap","year":"1993","journal-title":"Biotechnol Blood Proteins"},{"key":"10.1177\/0091270010372107-BIB38|cit38","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1007\/s00134-008-1225-2","article-title":"CRYCO Study Group. The risk associated with hyperoncotic colloids in patients with shock","volume":"34","author":"Schortgen","year":"2008","journal-title":"Intensive Care Med"},{"key":"10.1177\/0091270010372107-BIB39|cit39","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM199908053410603","article-title":"Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis","volume":"341","author":"Sort","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1177\/0091270010372107-BIB40|cit40","doi-asserted-by":"crossref","first-page":"R34","DOI":"10.1186\/cc6812","article-title":"Small-volume resuscitation with hyperoncotic albumin: a systematic review of randomized clinical trials","volume":"12","author":"Jacob","year":"2008","journal-title":"Crit Care"},{"key":"10.1177\/0091270010372107-BIB41|cit41","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1126\/science.42.1076.223","article-title":"On hydration and \u201csolution\u201d in gelatin","volume":"42","author":"Fischer","year":"1915","journal-title":"Science"},{"key":"10.1177\/0091270010372107-BIB42|cit42","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1042\/BA20030149","article-title":"Inactivation of the bovine-spongiform-encephalopathy (BSE) agent by the acid and alkaline processes used in the manufacture of bone gelatine","volume":"39","author":"Grobben","year":"2004","journal-title":"Biotechnol Appl Biochem"},{"key":"10.1177\/0091270010372107-BIB43|cit43","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1001\/archsurg.139.5.552","article-title":"A systematic review of the comparative safety of colloids","volume":"139","author":"Barron","year":"2004","journal-title":"Arch Surg"},{"key":"10.1177\/0091270010372107-BIB44|cit44","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/bja\/88.4.475","article-title":"In vivo effect of haemodilution with saline on coagulation: a randomized controlled trial","volume":"88","author":"Ng","year":"2002","journal-title":"Br J Anaesth"},{"key":"10.1177\/0091270010372107-BIB45|cit45","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1365-2141.1994.tb04878.x","article-title":"Prevalence of antithrombin deficiency in the healthy population","volume":"87","author":"Tait","year":"1994","journal-title":"Br J Haematol"},{"key":"10.1177\/0091270010372107-BIB46|cit46","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/bja\/78.6.684","article-title":"Effect of progressive haemodilution with hydroxyethyl starch, gelatin and albumin on blood coagulation","volume":"78","author":"Egli","year":"1997","journal-title":"Br J Anaesth"},{"key":"10.1177\/0091270010372107-BIB47|cit47","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1213\/01.ane.0000200285.20510.b6","article-title":"Gelatin and hydroxyethyl starch, but not albumin, impair hemostasis after cardiac surgery","volume":"102","author":"Niemi","year":"2006","journal-title":"Anesth Analg"},{"key":"10.1177\/0091270010372107-BIB48|cit48","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1007\/BF03022250","article-title":"The effects of colloid solutions on hemostasis","volume":"53","author":"Linden","year":"2006","journal-title":"Can J Anaesth"},{"key":"10.1177\/0091270010372107-BIB49|cit49","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/bja\/82.2.175","article-title":"Thrombelastogram reveals hypercoagulability after administration of gelatin solution","volume":"82","author":"Karoutsos","year":"1999","journal-title":"Br J Anaesth"},{"key":"10.1177\/0091270010372107-BIB50|cit50","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1399-6576.2005.00619.x","article-title":"Artificial colloids impair haemostasis. An in vitro study using thromboelastometry coagulation analysis","volume":"49","author":"Niemi","year":"2005","journal-title":"Acta Anaesthesiol Scand"},{"key":"10.1177\/0091270010372107-BIB51|cit51","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1055\/s-0037-1614979","article-title":"Impaired haemostasis by intravenous administration of a gelatin-based plasma expander in human subjects","volume":"79","author":"Jonge","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1177\/0091270010372107-BIB52|cit52","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1055\/s-0038-1660100","article-title":"Effect of dextran on factor VIII\/von Willebrand factor structure and function","volume":"54","author":"Batlle","year":"1985","journal-title":"Thromb Haemost"},{"key":"10.1177\/0091270010372107-BIB53|cit53","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1046\/j.1537-2995.1985.25485273815.x","article-title":"Effects of hydroxyethyl starch on blood coagulation, particularly factor VIII","volume":"25","author":"Stump","year":"1985","journal-title":"Transfusion"},{"key":"10.1177\/0091270010372107-BIB54|cit54","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1055\/s-0038-1661096","article-title":"Studies on the procurement of coagulation factor VIII: selective precipitation of factor VIII with hydrophilic polymers","volume":"51","author":"Farrugia","year":"1984","journal-title":"Thromb Haemost"},{"key":"10.1177\/0091270010372107-BIB55|cit55","first-page":"97","volume-title":"Plasma Volume Expansion","author":"Samama","year":"1992"},{"key":"10.1177\/0091270010372107-BIB56|cit56","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S0750-7658(97)80189-X","article-title":"Hydroxyethyl starch: effects on hemostasis","volume":"17","author":"Treib","year":"1998","journal-title":"Ann Fr Anesth R\u00e9anim"},{"key":"10.1177\/0091270010372107-BIB57|cit57","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1213\/00000539-200004000-00006","article-title":"Does intraoperative hetastarch administration increase blood loss and transfusion requirements after cardiac surgery","volume":"90","author":"Knutson","year":"2000","journal-title":"Anesth Analg"},{"key":"10.1177\/0091270010372107-BIB58|cit58","first-page":"989","article-title":"Compromised blood coagulation: an in vitro comparison of hydroxyethyl starch 130\/0.4 and hydroxyethyl starch 200\/0.5 using thrombelastography","volume":"87","author":"Jamnicki","year":"1998","journal-title":"Anesth Analg"},{"key":"10.1177\/0091270010372107-BIB59|cit59","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1097\/00000542-200612000-00023","article-title":"Effect of high- and low-molecular weight low-substituted hydroxyethyl starch on blood coagulation during acute normovolemic hemodilution in pigs","volume":"105","author":"Thyes","year":"2006","journal-title":"Anesthesiology"},{"key":"10.1177\/0091270010372107-BIB60|cit60","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1213\/01.ane.0000200297.98089.ce","article-title":"Fibrinogen concentrate reverses dilutional coagulopathy induced in vitro by saline but not by hydroxyethyl starch 6%","volume":"102","author":"Lorenzo","year":"2006","journal-title":"Anesth Analg"},{"key":"10.1177\/0091270010372107-BIB61|cit61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00126839-200405010-00001","article-title":"Volume efficacy and reduced influence on measures of coagulation using hydroxyethyl starch 130\/0.4 (6%) with an optimised in vivo molecular weight in orthopaedic surgery: a randomised, double-blind study","volume":"5","author":"Jungheinrich","year":"2004","journal-title":"Drugs R D"},{"key":"10.1177\/0091270010372107-BIB62|cit62","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/BF03019870","article-title":"A novel hydroxyethyl starch (Voluven) for effective perioperative plasma volume substitution in cardiac surgery","volume":"47","author":"Gallandat","year":"2000","journal-title":"Can J Anaesth"},{"key":"10.1177\/0091270010372107-BIB63|cit63","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1097\/00000539-200104000-00011","article-title":"Voluven, a lower substituted novel hydroxyethyl starch (HES 130\/0.4), causes fewer effects on coagulation in major orthopedic surgery than HES 200\/0.5","volume":"92","author":"Langeron","year":"2001","journal-title":"Anesth Analg"},{"key":"10.1177\/0091270010372107-BIB64|cit64","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1213\/ane.0b013e31817e6eac","article-title":"The effects of hydroxyethyl starch 130\/0.4 (6%) on blood loss and use of blood products in major surgery: a pooled analysis of randomized clinical trials","volume":"107","author":"Kozek-Langenecker","year":"2008","journal-title":"Anesth Analg"},{"key":"10.1177\/0091270010372107-BIB65|cit65","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1213\/ane.0b013e31818ee39d","article-title":"Hydroxyethyl starch 130\/0.4 and surgical blood loss","volume":"108","author":"Harzog","year":"2009","journal-title":"Anesth Analg"},{"key":"10.1177\/0091270010372107-BIB66|cit66","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1034\/j.1399-6576.2003.00220.x","article-title":"Equivalence of hydroxyethyl starch HES 130\/0.4 and HES 200\/0.5 for perioperative volume replacement in major gynaecological surgery","volume":"47","author":"Sander","year":"2003","journal-title":"Acta Anaesthesiol Scand"},{"key":"10.1177\/0091270010372107-BIB67|cit67","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/bja\/aen353","article-title":"Influence on coagulation of a potato-derived hydroxethylstarch (HES 130\/0.42) and a maize-derived hydroxethylstarch (HES 130\/0.4) in patients undergoing cardiac surgery","volume":"102","author":"Boldt","year":"2009","journal-title":"Br J Anaesth"},{"key":"10.1177\/0091270010372107-BIB68|cit68","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1213\/01.ANE.0000061582.09963.FD","article-title":"Repetitive large-dose infusion of the novel hydroxyethyl starch 130\/0.4 in patients with severe head injury","volume":"96","author":"Neff","year":"2003","journal-title":"Anesth Analg"},{"key":"10.1177\/0091270010372107-BIB69|cit69","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/00000542-200307000-00010","article-title":"Large-dose hydroxyethyl starch 130\/0.4 does not increase blood loss and transfusion requirements in coronary artery bypass surgery compared with hydroxyethyl starch 200\/0.5 at recommended doses","volume":"99","author":"Kasper","year":"2003","journal-title":"Anesthesiology"},{"key":"10.1177\/0091270010372107-BIB70|cit70","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1213\/ane.0b013e31818c1282","article-title":"Rapidly degradable hydroxyethyl starch solutions impair blood coagulation after cardiac surgery: a prospective randomized trial","volume":"108","author":"Schramko","year":"2009","journal-title":"Anesth Analg"},{"key":"10.1177\/0091270010372107-BIB71|cit71","unstructured":"Review of Voluven 2007 http:www.fda.govBiologicsBloodVaccinesBloodBloodProductsApprovedProductsNewDrugApplicationsNDAsucm083145.htm"},{"key":"10.1177\/0091270010372107-BIB72|cit72","first-page":"575","article-title":"Treatment of inadequate cerebral circulation. A critical review","volume":"15","author":"Gottstein","year":"1974","journal-title":"Internist (Berl)"},{"key":"10.1177\/0091270010372107-BIB73|cit73","first-page":"661","article-title":"Renal failure after the administration of dextran 40","volume":"131","author":"Matheson","year":"1970","journal-title":"Surg Gynecol Obstet"},{"key":"10.1177\/0091270010372107-BIB74|cit74","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1056\/NEJM198707163170306","article-title":"Acute renal failure associated with elevated plasma oncotic pressure","volume":"317","author":"Moran","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1177\/0091270010372107-BIB75|cit75","first-page":"52","article-title":"Hydroxyethyl starch induced transient renal failure in preexisting glomerular damage","volume":"18","author":"Waldhausen","year":"1991","journal-title":"Acta Med Austriaca"},{"key":"10.1177\/0091270010372107-BIB76|cit76","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa070716","article-title":"Intensive insulin therapy and pentastarch resuscitation in severe sepsis","volume":"358","author":"Brunkhorst","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1177\/0091270010372107-BIB77|cit77","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00134-003-1702-6","article-title":"Influence of two different volume replacement regimens on renal function in elderly patients undergoing cardiac surgery: comparison of a new starch preparation with gelatin","volume":"29","author":"Boldt","year":"2003","journal-title":"Intensive Care Med"},{"key":"10.1177\/0091270010372107-BIB78|cit78","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1213\/00000539-200209000-00007","article-title":"The pharmacokinetics and tolerability of an intravenous infusion of the new hydroxyethyl starch 130\/0.4 (6%, 500 mL) in mild-to-severe renal impairment","volume":"95","author":"Jungheinrich","year":"2002","journal-title":"Anesth Analg"},{"key":"10.1177\/0091270010372107-BIB79|cit79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-227X-8-1","article-title":"Systematic review of randomized clinical trials on the use of hydroxyethyl starch for fluid management in sepsis","volume":"8","author":"Wiedermann","year":"2008","journal-title":"BMC Emerg Med"},{"key":"10.1177\/0091270010372107-BIB80|cit80","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1136\/bmj.299.6708.1137","article-title":"Acute renal failure after infusion of gelatins","volume":"299","author":"Hussain","year":"1989","journal-title":"BMJ"},{"key":"10.1177\/0091270010372107-BIB81|cit81","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0140-6736(93)92345-T","article-title":"Hydroxyethylstarch and osmotic-nephrosis-like lesions in kidney transplantation","volume":"342","author":"Legendre","year":"1993","journal-title":"Lancet"},{"key":"10.1177\/0091270010372107-BIB82|cit82","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1016\/S0140-6736(96)07588-5","article-title":"Effect of hydroxyethylstarch in brain-dead kidney donors on renal function in kidney-transplant recipients","volume":"348","author":"Cittanova","year":"1996","journal-title":"Lancet"},{"key":"10.1177\/0091270010372107-BIB83|cit83","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/bja\/aen001","article-title":"Comparison of the novel hydroxyethylstarch 130\/0.4 and hydroxyethylstarch 200\/0.6 in braindead donor resuscitation on renal function after transplantation","volume":"100","author":"Blasco","year":"2008","journal-title":"Br J Anaesth"},{"key":"10.1177\/0091270010372107-BIB84|cit84","first-page":"e196","article-title":"Renal outcomes and mortality following hydroxyethyl starch resuscitation of critically ill patients: systematic review and meta-analysis of randomized trials","volume":"3","author":"Zarychanski","year":"2009","journal-title":"Open Medicine"},{"key":"10.1177\/0091270010372107-BIB85|cit85","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007594.pub2","article-title":"Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function","author":"Dart","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1177\/0091270010372107-BIB86|cit86","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/bja\/85.6.887","article-title":"Production of human albumin solution: a continually developing colloid","volume":"85","author":"Matejtschuk","year":"2000","journal-title":"Br J Anaesth"},{"key":"10.1177\/0091270010372107-BIB87|cit87","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1007\/s001340051085","article-title":"Certain batches of albumin solutions influence the expression of endothelial cell adhesion molecules","volume":"25","author":"Noh\u00e9","year":"1999","journal-title":"Intensive Care Med"},{"key":"10.1177\/0091270010372107-BIB88|cit88","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1055\/s-2001-919056","article-title":"Albumin binding capacity (ABiC) is reduced in commercially available human serum albumin preparations with stabilizers","volume":"39","author":"Klammt","year":"2001","journal-title":"Z Gastroenterol"},{"key":"10.1177\/0091270010372107-BIB89|cit89","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s001340051300","article-title":"Different batches of human albumin solutions from one manufacturer may induce heterogenous cardiovascular effects","volume":"26","author":"Heringlake","year":"2000","journal-title":"Intensive Care Med"},{"key":"10.1177\/0091270010372107-BIB90|cit90","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1213\/01.ane.0000221179.07006.06","article-title":"The value of an albumin-based intravascular volume replacement strategy in elderly patients undergoing major abdominal surgery","volume":"103","author":"Boldt","year":"2006","journal-title":"Anesth Analg"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F0091270010372107","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1177\/0091270010372107","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T12:57:17Z","timestamp":1657803437000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1177\/0091270010372107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":90,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"URL":"https:\/\/doi.org\/10.1177\/0091270010372107","relation":{},"ISSN":["0091-2700"],"issn-type":[{"value":"0091-2700","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}